Pfizer (PFE) Current Deferred Revenue (2020 - 2025)

Pfizer (PFE) has 6 years of Current Deferred Revenue data on file, last reported at $784.0 million in Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $784.0 million, down 48.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $784.0 million (down 48.11% YoY), and the FY2025 annual result was $784.0 million, down 48.11% from the prior year.
• Current Deferred Revenue fell to $784.0 million in Q4 2025 per PFE's latest filing, from $924.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $6.2 billion in Q4 2022 and troughed at $784.0 million in Q4 2025.
• A 5-year average of $2.4 billion and a median of $2.4 billion in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2021 and 2023: Current Deferred Revenue surged 175.56% in 2021, then tumbled 66.19% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $3.1 billion in 2021, then decreased by 17.84% to $2.5 billion in 2022, then grew by 7.14% to $2.7 billion in 2023, then tumbled by 44.04% to $1.5 billion in 2024, then sank by 48.11% to $784.0 million in 2025.
• Business Quant data shows PFE's Current Deferred Revenue at $784.0 million in Q4 2025, $924.0 million in Q3 2025, and $1.1 billion in Q2 2025.